| Discovery | Hit ID (virtual screening) | Lead optimization | Development candidate nomination |
|---|
Program 1
Development candidate nomination
Program 2
Hit ID (virtual screening)
Program 1 (obesity oral triple agent)
Lead optimization
Program 2 (obesity non-GLP1 target)
Lead optimization
Program 3 (obesity non-GLP1 target)
Hit ID (virtual screening)
Program 1
Lead optimization
Various programs – undisclosed
Lead optimization
GPCRs, the largest family of cell surface receptors, play cell signalling roles ubiquitous across biology. In fact, about a third of all proteins targeted by FDA-approved drugs are GPCRs. However, these drugs only address 108 out of the more than 400 members of the GPCR family of proteins. The majority of GPCRs therefore represent a significant number of potential targets with an emerging and untapped role in human diseases. In particular, biased signaling represents an area of significant opportunity that is a specific focus of Deep Apple’s drug discovery activities.
Research conducted at the Stanford lab of Deep Apple founder Georgios Skiniotis has enabled broad structural exploration of GPCR inactive states without the need for extensive engineering and crystallization – an approach that opens these drug targets to rapid structure determination.
Beyond GPCRs, Deep Apple’s discovery engine is readily adaptable to all other biological targets implicated in human disease. In particular, our discovery engine is well-suited to focus on transporter and ion channel target classes.
Deep Apple’s lead programs address a high value target in the inflammatory/immune pathway and several targets for weight loss and weight maintenance, including non-GLP1 targets. The oral therapeutics Deep Apple is developing in these areas are designed to offer significant tolerability and convenience compared to existing and emerging treatment options.
Deep Apple’s rapid discovery and optimization platform is optimally suited to partnered discovery and development. Deep Apple is equipped to run swift explorations in target areas of interest and invites partnership discussions across a broad range of targets and disease areas.
